FindTrial
Sign In

The Incidence of Urticaria, Angioedema, and Type I Hypersensitivity Reactions with Fibrinolytic Agents in Thailand Using Health Product Vigilance Center Database

The Incidence of Urticaria, Angioedema, and Type I Hypersensitivity Reactions with Fibrinolytic Agents in Thailand Using Health Product Vigilance Center Database

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20191030004
Enrollment
Unknown
Registered
2019-10-30
Start date
2018-07-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The aim of study was to analyze the incidence of urticaria angioedema and type I hypersensitivity reactions from fibrinolytic agents in various indications anaphylaxis&#44

Interventions

Fibrinolytics used and hypersensitivity type I occurs
Screening
Fibrinolytics Use

Sponsors

Faculty of Pharmacy, Silpakorn University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All reports of urticaria, angioedema, or type I hypersensitivity reactions caused due to streptokinase, alteplase, and TNK were enrolled, and any reports described as “unlikely” based on Naranjo probability scale was excluded. Terms specified in the spontaneous reporting system according to the WHO adverse reaction terminology (WHO-ART) were used for identifying the reactions

Exclusion criteria

Exclusion criteria: No data about important

Design outcomes

Primary

MeasureTime frame
Incidence of allergy 5 years Incidence—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public ContactPORNWALAI BOONMUANG

Faculty of Pharmacy, Silpakorn University

pharm_md@hotmail.com0956519822

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026